ANMCO statement on the use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure: a practical guide for a streamlined implementation

Sodium-glucose cotransporter 2 (SGLT2) inhibitors, dapagliflozin, and empagliflozin, first developed as glucose-lowering agents for the treatment of Type 2 diabetes, have been demonstrated to improve prognosis in patients with heart failure and reduced ejection fraction (HFrEF) regardless of the pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Fusco, Stefania Angela, Gronda, Edoardo, Mocini, Edoardo, Lucà, Fabiana, Bisceglia, Irma, De Luca, Leonardo, Caldarola, Pasquale, Cipriani, Manlio, Corda, Marco, De Nardo, Alfredo, Francese, Giuseppina Maura, Napoletano, Cosimo, Navazio, Alessandro, Riccio, Carmine, Roncon, Loris, Tizzani, Emanuele, Nardi, Federico, Urbinati, Stefano, Valente, Serafina, Gulizia, Michele Massimo, Gabrielli, Domenico, Oliva, Fabrizio, Imperoli, Giuseppe, Colivicchi, Furio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Position Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117908/
https://www.ncbi.nlm.nih.gov/pubmed/35602255
http://dx.doi.org/10.1093/eurheartj/suac017
Descripción
Sumario:Sodium-glucose cotransporter 2 (SGLT2) inhibitors, dapagliflozin, and empagliflozin, first developed as glucose-lowering agents for the treatment of Type 2 diabetes, have been demonstrated to improve prognosis in patients with heart failure and reduced ejection fraction (HFrEF) regardless of the presence of diabetes. Since these drugs have only recently been included among the four pillars of HFrEF treatment, cardiologists are still unfamiliar with their use in this setting. This article provides an up-to-date practical guide for the initiation and monitoring of patients treated with SGLT2 inhibitors.

Ejemplares similares